Hi Frank, the Company has also quite clearly stressed that there...

Hi Frank, the Company has also quite clearly stressed that there is no assurance it will be done in a timely manner, and also used the word ‘potentially’ too, which has been rather transparent by the Company for once. Looks like there will be at least the one CR before that main event, two if not done this year.

From right field would be a Trading Halt Ann that will announce that funds will be raised via a IPO negating a CR in Australia that is drawing pretty close.
Unfortunately with the history of Allied Health, Admedus and now Anteris ‘nice surprises’ are few and far between on the financial front.

The ‘what next’ all hinges on where future funding is coming from, how much and at what sp levels funds raised at to progress the IP, any number of patents and irons in the fire are just ‘potential’ until such time you have a blank cheque available.

The current R&D spend is minuscule compared to what the main Competitors are spending.

Reality check is that maybe the sp is actually fair value taking into account that a massive amount of funding is still required to get to commercialisation stage. Amount of funding would be what?, potentially a few hundred million?

So for a take over bid to be considered, say, you have to factor in the current MC plus what it would cost to include the options plus the amount of R&D into bringing the IP to fruition.

With the above scenario, Company is at fair value, than WP is doing a great job though negated to an extent with the spiel he puts out regarding internal valuations, suitors in the wings, ect, ect, not sure why he needed to do this for and had not tempered that spiel; as per NASDAQ qualification example.

Just my thoughts and not necessarily correct though I don’t believe groundless.

Imho, not advice.